RZLT · Rezolute, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-02 | Elam Nevan C |
Director, CEO |
Tax↓
Filing footnotes — Common Shares (Direct)
The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Common Shares
|
8,004 |
| 2026-07-02 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Shares (Direct)
The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Common Shares
|
3,062 |
| 2026-07-02 | Evans Daron |
CFO |
Tax↓
Filing footnotes — Common Shares (Direct)
The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Common Shares
|
3,062 |
| 2026-03-30 | Evans Daron |
CFO |
Buy↑
|
Common Shares
|
10,000 |
| 2026-03-02 | Evans Daron |
CFO |
Tax↓
Filing footnotes — Common Shares (Direct)
The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Shares
|
11,438 |
| 2026-03-02 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Shares (Direct)
The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07 inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Shares
|
11,439 |
| 2026-03-02 | Elam Nevan C |
Director, CEO |
Tax↓
Filing footnotes — Common Shares (Direct)
The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Shares
|
27,618 |
| 2025-12-16 | Hogenhuis Wladimir |
Director |
Buy↑
|
Common Shares
|
5,650 |
| 2025-12-16 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Buy↑
|
Common Shares
|
28,000 |
| 2025-12-15 | Evans Daron |
CFO |
Buy↑
Filing footnotes — Common Shares (Indirect)
The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.78 to $1.79, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Common Shares
(I)
|
2,500 |
| 2025-12-15 | Karnawat Sunil Ratilal |
Chief Commercial Officer |
Buy↑
|
Common Shares
|
100 |
| 2025-12-15 | Evans Daron |
CFO |
Buy↑
Filing footnotes — Common Shares (Direct)
The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.81, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Common Shares
|
40,000 |
| 2025-12-15 | Karnawat Sunil Ratilal |
Chief Commercial Officer |
Buy↑
|
Common Shares
|
12,000 |
| 2025-12-15 | Elam Nevan C |
Director, CEO |
Buy↑
|
Common Shares
|
32,000 |
| 2025-12-15 | Evans Daron |
CFO |
Buy↑
|
Common Shares
(I)
|
2,500 |
| 2025-12-09 | Evans Daron |
CFO |
Buy↑
Filing footnotes — Common Shares (Direct)
The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.985 to $5.0559, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Common Shares
|
10,549 |
| 2025-11-19 | FAUCHET PHILIPPE |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options fully vest on December 1, 2026.. |
Director Stock Option (Right to Buy)
|
12,000 |
| 2025-11-19 | Elam Nevan C |
Director, CEO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. |
Common Shares
|
317,000 |
| 2025-11-19 | Labrucherie Gil M |
SVP, COO & CFO |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options fully vest on December 1, 2026. |
Director Stock Option (Right to Buy)
|
12,000 |
| 2025-11-19 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. |
Common Shares
|
123,000 |
| 2025-11-19 | Harris Erik |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options fully vest on December 1, 2026. |
Director Stock Option (Right to Buy)
|
12,000 |
| 2025-11-19 | Evans Daron |
CFO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options vest 1/36th monthly beginning on December 19, 2025. |
Employee Stock Option (Right to Buy)
|
63,000 |
| 2025-11-19 | KREHER NERISSA |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options fully vest on December 1, 2026. |
Director Stock Option (Right to Buy)
|
12,000 |
| 2025-11-19 | Elam Nevan C |
Director, CEO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options vest 1/36th monthly beginning on December 19, 2025. |
Employee Stock Option (Right to Buy)
|
186,000 |
| 2025-11-19 | Hogenhuis Wladimir |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options fully vest on December 1, 2026. |
Director Stock Option (Right to Buy)
|
12,000 |
| 2025-11-19 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Other↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options vest 1/36th monthly beginning on December 19, 2025. |
Employee Stock Option (Right to Buy)
|
72,000 |
| 2025-11-19 | Kim Young-Jin |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which fully vest on December 1, 2026. |
Common Shares
|
21,000 |
| 2025-11-19 | Evans Daron |
CFO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. |
Common Shares
|
107,000 |
| 2025-11-19 | KREHER NERISSA |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which fully vest on December 1, 2026. |
Common Shares
|
21,000 |
| 2025-11-19 | Karnawat Sunil Ratilal |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. |
Common Shares
|
32,000 |
| 2025-11-19 | Kim Young-Jin |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options fully vest on December 1, 2026. |
Director Stock Option (Right to Buy)
|
12,000 |
| 2025-11-19 | Harris Erik |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which fully vest on December 1, 2026. |
Common Shares
|
21,000 |
| 2025-11-19 | Karnawat Sunil Ratilal |
Chief Commercial Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options vest 1/36th monthly beginning on December 19, 2025. |
Employee Stock Option (Right to Buy)
|
19,000 |
| 2025-11-19 | FAUCHET PHILIPPE |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which fully vest on December 1, 2026. |
Common Shares
|
21,000 |
| 2025-11-19 | Hogenhuis Wladimir |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which fully vest on December 1, 2026. |
Common Shares
|
21,000 |
| 2025-11-19 | Labrucherie Gil M |
SVP, COO & CFO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which fully vest on December 1, 2026. |
Common Shares
|
21,000 |
| 2025-08-18 | Karnawat Sunil Ratilal |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest as follows: 1/4 on September 1, 2026; 1/4 on September 1, 2027; 1/4 on September 1, 2028; and 1/4 on September 1, 2029. |
Common Shares
|
25,000 |
| 2025-08-18 | Karnawat Sunil Ratilal |
Chief Commercial Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options shall vest and become exercisable as follows: One fourth (1/4) of such Options shall vest on the one-year anniversary of the grant date and one thirty-sixth (1/36) of the remaining Options shall vest on the same day of each month thereafter until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Reporting Person's termination of continuous service. |
Employee Stock Option (Right to Buy)
|
275,000 |
| 2025-06-25 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Buy↑
Filing footnotes — Common Shares (Direct)
The purchaes price reported above is a weight average price. These shares were purchased in multiple transactions at prices ranging from $4.37 to $4.38, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Common Shares
|
2,500 |
| 2025-06-24 | Evans Daron |
CFO |
Buy↑
|
Common Shares
|
5,000 |
| 2025-06-13 | Kim Young-Jin |
Director |
Buy↑
Filing footnotes — Common Shares (Indirect)
The reporting person disclaims beneficial ownership of the securities held by Handok, Inc. except to the extent of his pecuniary interest therein, if any. |
Common Shares
(I)
|
1,230,769 |
| 2025-06-13 | KREHER NERISSA |
Director |
Buy↑
|
Common Shares
|
3,076 |
| 2025-06-10 | Elam Nevan C |
Director, CEO |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest as follows: 1/3 on July 1, 2026; 1/3 on July 1, 2027; and 1/3 on July 1, 2028. |
Common Shares
|
68,000 |
| 2025-06-10 | ROBERTS BRIAN KENNETH |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options vest as follows: 1/36th monthly beginning on July 10, 2025. |
Employee Stock Option (Right to Buy)
|
15,000 |
| 2025-06-10 | Kim Young-Jin |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options vest 100% on July 1, 2026. |
Director Stock Option (Right to Buy)
|
5,000 |
| 2025-06-10 | Hogenhuis Wladimir |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest 100% on July 1, 2026. |
Common Shares
|
9,000 |
| 2025-06-10 | Kim Young-Jin |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Represents grant of restricted stock units which vest 100% on July 1, 2026. |
Common Shares
|
9,000 |
| 2025-06-10 | FAUCHET PHILIPPE |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options vest 100% on July 1, 2026. |
Director Stock Option (Right to Buy)
|
5,000 |
| 2025-06-10 | Evans Daron |
CFO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The options vest as follows: 1/36th monthly beginning on July 10, 2025. |
Employee Stock Option (Right to Buy)
|
15,000 |
| 2025-06-10 | Labrucherie Gil M |
SVP, COO & CFO |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The options vest 100% on July 1, 2026. |
Director Stock Option (Right to Buy)
|
5,000 |